Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Peg lambda cuts hospitalization, ER visits in COVID-19 outpatients
Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.
COVID-19 infection in early pregnancy ups risk of stillbirth
Pregnant women who contract COVID-19 during early and mid-pregnancy are at risk of stillbirth, but this risk may not be present when infection occurs at any time during the third trimester or before delivery, as reported in a study.
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.
Post-treatment neutrophil, lymphocyte counts offer clues to Hodgkin’s lymphoma prognosis
For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.